๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ningbo
Clinical trial register · China

Clinical Trials in Ningbo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
First Affiliated Hospital of Ningbo University19 Second Affiliated Hospital, Zhejiang University, School of Medicine15 Ningbo Medical Center Lihuili Hospital10 Ningbo No. 1 Hospital8 Janssen Research & Development, LLC7
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Ningbo

143 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neoadjuvant Therapy of HAIC๏ผˆGEMOX๏ผ‰ Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT06208462Intrahepatic Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
33
Nanjing, Chengdu, Ningbo
2024-01-19
Recruiting
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease๏ผˆOCEAN PROJECT๏ผ‰
NCT06368882Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b
First Affiliated Hospital of Wenzhou Medical University
Phase 4
1,500
Ningbo, Ruiโ€™an, Wenzhou, Yueqing
2024-01-01
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
Yu jiren
Phase 2
314
Hangzhou, Lishui, Ningbo, Taizhou
2023-12-24
Recruiting
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
NCT06188650Non-Small Cell Lung Cancer
Ningbo Medical Center Lihuili Hospital
Not applicable
30
Ningbo
2023-12-09
Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
Women's Hospital School Of Medicine Zhejiang University
Phase 3
538
Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou
2023-11-27
Recruiting
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
NCT05692882Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents, Intracranial Artery Stenosis
Sino Medical Sciences Technology Inc.
Not applicable
1,000
Chenzhou, Ganzhou, Jinhua, Ningbo, Shanxi
2023-11-16
Active, closed
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
NCT06825312Japanese Encephalitis Vaccine
Liaoning Chengda Biotechnology CO., LTD
Phase 4
600
Jiaxing, Jinhua, Ningbo, Quzhou
2023-11-11
Recruiting
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized๏ผŒOpen-label Clinical Trial.
NCT06079788Nephrotic Syndrome in Children
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
Cardiovascular Risk Assessment and Dynamic Monitoring-based Prevention Trial
NCT05919056Cardiovascular Diseases
Peking University
Not applicable
22,032
Ningbo
2023-07-06
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Recruiting
A Randomized Controlled Study Evaluating Modified Cup Anteversion Placement in Prevention of Postoperative Dislocation in Patients Undergoing Acetabular Tumor Resection and Reconstruction
NCT05593146Periacetabular Tumor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
118
Ningbo
2023-04-13
Active, closed
Efficacy of taVNS Versus Sham Stimulation in Reduing Depressive Symptoms in Patients With Epilepsy: a Multi-center, Double-blinded, Randomized, 20-week, Parallel-arm, Superiority Study
NCT06794034Depressive Symptoms in Patients With Epilepsy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
158
Hangzhou, Jiaxing, Jinhua, Ningbo, Yiwu
2023-04-01
Recruiting
Combined Screening for Gastrointestinal Tumors
NCT06478030Gastrointestinal Tumors
Zhejiang Cancer Hospital
Observational
200,000
Jinhua, Ningbo
2023-03-01
Not yet open
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
NCT05699746Colorectal Cancer
Zhejiang University
Phase 3
38
Shanghai, Hangzhou, Ningbo
2023-03
Recruiting
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naรฏve Participants With Acute Myeloid Leukemia
NCT05736965AML, Adult
Shanghai Tong Ren Hospital
Phase 2
58
Changzhou, Chengdu, Chโ€™ang-chโ€™un, Haโ€™erbin, Hefei, Jiaxing, Lanzhou, Ningbo
2023-02-20
Active, closed
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
NCT05546866Non-small Cell Lung Cancer
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Recruiting
Clinical Study of OR for Second-line Treatment of Refractory MZL
NCT06134284OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng
Phase 4
39
Hangzhou, Ningbo
2023-01-02
Recruiting
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
NCT05659628Diffuse Large B-cell Lymphoma
Ningbo No. 1 Hospital
Phase 1
24
Hangzhou, Ningbo
2022-12
Active, closed
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
NCT05374603Lung Cancer
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Active, closed
Comparing Myopia Control Efficacy in Children With 4 Methods: Orthokeratology, DIMS, DISK, and SVS.
NCT06654180Myopia
Kaikai QIU
Not applicable
100
Ningbo
2022-10-21
Recruiting
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
NCT05446467Head and Neck Squamous Cell Carcinoma
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Active, closed
Optimizing Intervention Effects in Children and Adolescents
NCT05482165Childhood Obesity
Ningbo No. 1 Hospital
Not applicable
1,627
Ningbo
2022-09-01
Active, closed
Healthy Weight Management Project for Overweight and Obesity Children
NCT05482191Obesity
Ningbo No. 1 Hospital
Not applicable
331
Ningbo
2022-09-01
Recruiting
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
NCT05507411Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2
100
Hanzhou, Ningbo
2022-08-03
Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC
NCT05514275Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Recruiting
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
NCT05126160Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Observational
494
Wuhan, Ningbo, Wenzhou, Hangzhou
2021-11-05
Recruiting
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
NCT04974346Cervical Cancer
Zhejiang Cancer Hospital
Phase 3
455
Hangzhou, Jinhua, Lishui, Ningbo, Taizhou, Wanzhou
2021-08-02
Recruiting
Fecal Microbiota Transplantation for Liver Failure
NCT05170971Liver Failure
Ningbo Medical Center Lihuili Hospital
Not applicable
60
Ningbo
2021-05-01
Active, closed
Application of in Vivo Splitting Technique in Adult Liver Transplantation
NCT06925828Liver Transplantation
Ningbo Medical Center Lihuili Hospital
Observational
500
Ningbo
2021-01-01
Active, closed
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
NCT04513418Esophageal Neoplasms
Hecheng Li M.D., Ph.D
Phase 3
244
Shanghai, Hangzhou, Ningbo
2020-11-10
Recruiting
Abbott Vascular Medical Device Registry
NCT04573660Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
Abbott Medical Devices
Observational
3,784
Xi'an, Jinhua, Ningbo
2020-10-25
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Active, closed
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
NCT04547049Leukemia, MDS
First Affiliated Hospital of Zhejiang University
Phase 3
232
Changsha, Chongqing, Hangzhou, Nanjing, Ningbo, Suzhou
2020-09-01
Active, closed
Sustained Effect of Red-light Therapy for Myopia Control: A 2-Year Post-Trial Follow-up Study
NCT06232161Myopia
Beijing Airdoc Technology Co., Ltd.
Not applicable
50
Ningbo
2020-05-13
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC
Phase 3
765
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Ningbo, Shanghai
2019-01-25
Active, closed
Ningbo Schizophrenia Cohort
NCT06370793Schizophrenia
Ningbo University
Observational
26,899
Ningbo
2018-07-01
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xiโ€™an, Hangzhou, Ningbo
2018-04-24
Active, closed
Ningbo Maternity-Child Linked Database Study
NCT06422130Pregnant Women, Children
Ningbo University
Observational
325,596
Ningbo
2016-10-01
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Rows per page Showing 101–143 of 143
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/ningbo?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 143 of those studies with a site in Ningbo.

How many clinical trials are recruiting in Ningbo?

82 of the 143 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 27 have not yet opened recruitment, 25 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.